Novartis is building the case for its radioligand therapy. With positive phase 3 primary endpoint data in the bag, Novartis arrived at the European Society of Medical Oncology Congress 2021 armed with evidence of the therapy’s effect on quality of life and pain.
AstraZeneca is following suit of many other pharmas and tapping academic and cancer organizations to fill out its oncology research team.
Elevian thinks it has the tools to treat age-related diseases and will start by testing its drug in one of the leading causes of death: strokes. The Massachusetts biotech raised $40 million to bankroll studies based on research that emerged out of Harvard in the early 2010s.
A gloomy outlook in May has turned into a potential $190 million future for Travere Therapeutics’ late-stage kidney asset.
Barely a week after announcing its intent to debut on the London Stock Exchange, Oxford Nanopore Technologies has locked down an investor willing to snap up about half of the shares on offer.
IASO Biotherapeutics bagged a hefty $108 million to fuel a teeming pipeline of cell therapies and antibodies for cancer and autoimmune disease. The series C round brings the company’s total raised to more than $178 million.
Amolyt Pharma has secured $80 million in financing from the likes of Novo Holdings and comes just a week after moving forward with a PeptiDream collaboration.
Deciphering the inner workings of the brain to get to the root of neurological conditions like Parkinson’s disease and multiple sclerosis is a lot like translating ancient writing systems into our modern languages—but the aptly named Rune Labs is on the case.
Francis Medical’s thermal water vapor ablation technology is picking up steam—literally and figuratively. The technology heats sterilized water into steam, which is then directed at tumors via a catheter to kill only cancerous cells while preserving the surrounding tissue.
Biosplice Therapeutics is attempting to clear its late-stage knee osteoarthritis treatment after other biopharmas have reached snags in the past year, and it now has $140 million worth of confidence with a partner in China.